Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation (CTOT-09)

Project: Research project

Description

Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects.

The purpose of this CTOT study is to evaluate the safety of slowly removing tacrolimus therapy after treatment with ATG. The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus is stopped. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.

Using specimens obtained through the CTOT-09 clinical protocol, Dr. Ansari will perform the HLA-specific B cell assay and data analysis.
StatusFinished
Effective start/end date5/1/158/31/16

Funding

  • Icahn School of Medicine at Mount Sinai (025513504609//2U01AI06359411)
  • National Institute of Allergy and Infectious Diseases (025513504609//2U01AI06359411)

Fingerprint

Immunologic Monitoring
Kidney Transplantation
Kidney
Tacrolimus
Immunosuppression
Immune System
HLA-B Antigens
Kidney Diseases
Clinical Protocols
Pharmaceutical Preparations
B-Lymphocytes
Therapeutics
Safety
Research